Screener Summaries Updates Institutions Sign In More Updates › Financing › BSX Financing · Feb 26, 2026
Boston Scientific Corporation entered into new credit agreements totaling $11 billion to support general corporate… BSX Boston Scientific Corp
Boston Scientific Corporation entered into new credit agreements totaling $11 billion to support general corporate purposes and the acquisition of Penumbra, Inc. These facilities include a $3.0 billion revolving credit agreement, a $2.0 billion 364-day revolving credit agreement, and a $6.0 billion term loan agreement.
More from Boston Scientific Corp Boston Scientific reports Q3 net sales of $5.14B, up 1.5%, with adjusted EPS of $0.73 Oct 28, 2026 Boston Scientific promotes Joe Fitzgerald to COO and appoints Mark Bickel as Chief Accounting Officer Oct 7, 2026 Arthur C. Butcher retires as EVP of MedSurg and Asia Pacific at Boston Scientific Sep 23, 2026 Boston Scientific Corporation disclosed a material cybersecurity incident that began on August 25, 2026, causing… Sep 8, 2026 Boston Scientific reported second quarter 2026 net sales of $5.442 billion, a 7.5% increase on a reported basis and… Jul 29, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
